See more : Arbor Realty Trust, Inc. (ABR-PC) Income Statement Analysis – Financial Results
Complete financial analysis of BiVictriX Therapeutics Plc (BVX.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BiVictriX Therapeutics Plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Totalbanken A/S (TOTA.CO) Income Statement Analysis – Financial Results
- Aramex PJSC (ARMX.AE) Income Statement Analysis – Financial Results
- Park National Corporation (PRK) Income Statement Analysis – Financial Results
- IFB Agro Industries Limited (IFBAGRO.NS) Income Statement Analysis – Financial Results
- Beijing New Building Materials Public Limited Company (000786.SZ) Income Statement Analysis – Financial Results
BiVictriX Therapeutics Plc (BVX.L)
About BiVictriX Therapeutics Plc
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 165.00K | 151.00K | 46.00K | 1.00K | 0.00 | 0.00 |
| Gross Profit | -165.00K | -151.00K | -46.00K | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.88M | 2.11M | 711.00K | 305.00K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 738.00K | 567.00K | 211.00K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 0.00 |
| SG&A | 978.00K | 738.00K | 567.00K | 215.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 127.00K | 224.00K | 521.00K | 526.00K | 480.00K |
| Operating Expenses | 2.86M | 2.98M | 1.50M | 521.00K | 526.00K | 480.00K |
| Cost & Expenses | 3.03M | 2.98M | 1.50M | 521.00K | 526.00K | 480.00K |
| Interest Income | 22.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 641.00K | 19.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 165.00K | 151.00K | 46.00K | 1.00K | 171.86K | 161.14K |
| EBITDA | -2.86M | -2.82M | -1.46M | -520.00K | -526.00K | -480.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.03M | -2.98M | -1.89M | -490.00K | -526.00K | -480.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.00K | 4.00K | -1.03M | -19.00K | 0.00 | 0.00 |
| Income Before Tax | -3.00M | -2.97M | -2.53M | -509.00K | -526.00K | -480.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -458.00K | -474.00K | -193.00K | -84.00K | -117.00K | -102.00K |
| Net Income | -2.55M | -2.50M | -2.34M | -425.00K | -409.00K | -378.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.04 | -0.04 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | -0.02 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 72.65M | 66.12M | 66.12M | 23.97M | 66.12M | 66.12M |
| Weighted Avg Shares Out (Dil) | 72.65M | 66.12M | 66.12M | 23.97M | 66.12M | 66.12M |
Source: https://incomestatements.info
Category: Stock Reports